Emergent BioSolutions | EBS - Market Capitalization


Emergent BioSolutions reported $422.3M in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Akebia Therapeutics USD 427M 297M Dec/2025
ALKERMES USD 4.62B 333M Dec/2025
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
Amarin USD 290M 51M Dec/2025
ANI Pharmaceuticals USD 1.77B 269M Dec/2025
BioMarin Pharmaceutical USD 11.42B 1.02B Dec/2025
Coherus Biosciences USD 172M 19M Dec/2025
Emergent BioSolutions USD 125M 51M Dec/2023
Exelixis USD 11.75B 959M Dec/2025
Glaxosmithkline GBP 99.93B 13.05B Dec/2025
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
Lexicon Pharmaceuticals USD 418M 73M Dec/2025
Lonza CHF 39.68B 980.61M Jun/2025
Merck USD 261.26B 51.62B Dec/2025
Myriad Genetics USD 575M 98M Dec/2025
Nektar Therapeutics USD 14.34B 13.48B Apr/2026
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Pacira USD 1.06B 94M Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
PTC Therapeutics USD 5.26B 844M Apr/2026
Sanofi EUR 101.43B 1.16B Apr/2026
Sarepta Therapeutics USD 2.26B 238M Dec/2025
United Therapeutics USD 20.98B 2.02B Dec/2025
Vanda Pharmaceuticals USD 279M 6M Dec/2024